Drug intelligence / Profile preview

HBS-α-helicomimics

Development stage
Preclinical
Lead developer
Indian Institute of Technology, Kanpur
Modality
Peptides
01

Overview

HBS-α-helicomimics are a novel class of chemically engineered, α-helix mimicking polypeptides designed to target TMPRSS2-ERG fusion-driven prostate cancer. Developed by researchers at the Indian Institute of Technology Kanpur and the Indian Institute of Science Bangalore, these helicomimics utilize a Hydrogen Bond Surrogate (HBS) approach to stabilize the α-helical conformation, incorporating non-biodegradable N-terminal HBS-turns and a thermally stable backbone to enhance in vivo stability and DNA affinity. The mechanism of action involves specific binding to the ETS consensus DNA motif, which directly blocks the interaction between the ERG transcription factor and its target DNA sequences. This disruption inhibits ERG-mediated transcriptional activity and its oncogenic interactions with cofactors such as the androgen receptor (AR), leading to reduced proliferation, migration, and invasion in ERG-positive prostate cancer cells.

Other names
HBS-alpha-helicomimicsHydrogen Bond Surrogate alpha-helicomimics
02

Targets

ERG (ETS-related gene transcription factor ERG)DNA

Beyond the preview

Go deeper on HBS-α-helicomimics.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HBS-α-helicomimics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call